Use of a self-expanding super-elastic all-metal endoprosthesis; To treat degenerated SVG lesions: The SESAME first in man trial

Catheterization and Cardiovascular Interventions

Volumn 76, Issue 6, 2010, Pages 781-786

  Abizaid, Alexander ^a   Weiner, Bonnie ^b   Bailey, Steven R ^c   Londero, Hugo ^d  

^a Medical School   (Brazil)

^b Imaging Core Lab Services   (United States)

^c University of Texas Health Science Center   (United States)

^d Sanatorio Allende   (Argentina)

Author keywords

complications; devices; embolic protection; percutaneous coronary intervention; saphenous vein graft; thrombosis

Indexed keywords

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEVICE; FEMALE; FOLLOW UP; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MALE; MATERIAL COATING; MULTICENTER STUDY; PROSPECTIVE STUDY; RESTENOSIS; SAPHENOUS VEIN GRAFT; TREATMENT OUTCOME; VASCULAR PATENCY; VEIN GRAFT DISEASE; VEIN OCCLUSION; VEIN PROSTHESIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ARGENTINA; BRAZIL; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; FEMALE; GRAFT OCCLUSION, VASCULAR; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; SAPHENOUS VEIN; STENTS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL; VASCULAR PATENCY;

EID: 78649653067     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22687     Document Type: Article

References (25)

1. Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB, III, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997; 337: 740-747.
2. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S,. A randomized-controlled trial of a paclitaxel-eluting stent versus a similar bare metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009; 53: 919-928.
3. Vermeersch P, Agostoni P, Verheye S, et al. Randomized doubleblind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial. J Am Coll Cardiol 2006; 48: 2423-2431.
4. Safian RD, Kaplan B, Schreiber T, et al. Final results of the Wallstent endoprosthesis in large saphenous vein grafts (WINS Registry) [abstract]. J Am Coll Cardiol 1999; 33: 51A.
5. Nordrehaug JE, Priestley KA, Chronos NA, Rickards AF, Buller NP, Sigwart U,. Self expanding stents for the management of aorto-ostial stenoses in saphenous vein bypass grafts. Br Heart J 1994; 72: 285-287; doi: 10.1136/hrt.72.3.285.
6. Mathew V, Grill DE, Scott CG, Grantham JA, Ting HH, Garratt KN, Holmes DR Jr,. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J Am Coll Cardiol 1999; 34: 1163-1169.
7. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol EJ,. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials. Circulation 2002; 106: 3063-3067.
8. Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, et al. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: The randomized evaluation of polytetrafluoroethylene COVERed stent in saphenous vein grafts (RECOVERS) trial. Circulation 2003; 108: 37-42.
9. Giugliano GR, Kuntz RE, Popma JJ, Cutlip DE, Baim DS,. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol 2005; 95: 173-177.
10. Stone GW, Rogers C, Ramee S, White C, Kuntz RE, Popma JJ, George J, Almany S, Bailey S,. Distal filter protection during saphenous vein graft stenting: Technical and clinical correlates of efficacy. J Am Coll Cardiol 2002; 40: 1882-1888.
11. Mathew V, Lennon RJ, Rihal CS, Bresnahan JF, Holmes DR Jr,. Applicability of distal protection for aortocoronary vein graft interventions in clinical practice. Catheter Cardiovasc Interv 2004; 63: 148-151.
12. Webb JG, Carere RG, Virmani R, Baim D, Teirstein PS, et al. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol 1999; 34: 468-475.
13. Quan VH, Huynh R, Seifert PA, Kuchela A, Chen WH, Sutsch G, Eisenhauer AC, Rogers C,. Morphometric analysis of particulate debris extracted by four different embolic protection devices from coronary arteries, aortocoronary saphenous vein conduits, and carotid arteries. Am J Cardiol 2005; 95: 1415-1419.
14. Mauri L, Cox D, Hermiller J, Massaro J, Wahr J, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: A randomized, prospective, multicenter clinical trial. J Am Coll Cardiol 2007; 50: 1442-1449.
15. Mehta SK, Stolker JM, Frutkin AD, Marso SP,. Suitability of saphenous vein graft lesions for the use of distal embolic protection devices. J Invasive Cardiol 2008; 20: 568-570.
16. Matar FA, Smith K, Rossi P, Vandormael M, Sullebarger JT, Taylor M, Caruncho C, Ali T, Kerensky R,. Limitations of embolic protection in saphenous vein graft intervention: Insights from 202 consecutive patients. J Interv Cardiol 2009; 22: 240-246.
17. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
18. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52. (Pubitemid 29035956)
19. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R,. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002; 105: 2974-2980. (Pubitemid 34693829)
20. Sprague EA, Palmaz JC,. A model system to assess key vascular responses to biomaterials. J Endovasc Ther 2005; 12: 594-604.
21. Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, et al. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. JACC Cardiovasc Interv 2009; 2: 855-860.
22. Coolong A, Baim DS, Kuntz RE, O'Malley AJ, Marulkar S, Cutlip DE, Popma JJ, Mauri L,. Saphenous vein graft stenting and major adverse cardiac events: A predictive model derived from a pooled analysis of 3958 patients. Circulation 2008; 117: 790-797.
23. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AHM, Bonneau HN, Leon MB, Moses JW, Yock PG, Honda Y, Kuntz RE, Fitzgerald PJ,; SIRIUS Investigators. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 2004; 43: 1959-1963.
24. Turco MA, Buchbinder M, Popma JJ, Weissman NJ, Mann T, Doucet S, Johnson WL Jr, Greenberg JD, Leadley K, Russell ME,. Pivotal, randomized U.S. study of the Symbiottrade mark covered stent system in patients with saphenous vein graft disease: eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv 2006; 68: 379-388.
25. Stone GW, Goldberg S, Mehran R, et al. A prospective, randomized US trial of the PTFE covered JOSTENT for the treatment of diseased saphenous vein grafts: The BARRICADE trial (abstr) J Am Coll Cardiol 2005; 45: 27.